Phase II trial of tanespimycin (KOS-953), a heat shock protein-90 (Hsp90) inhibitor in patients with metastatic melanoma

被引：0
|
作者：
Kefford, R.
Millward, M.
Hersey, P.
Brady, B.
Graham, M.
Johnson, R. G.
Hannah, A. L.
机构：
[1] Westmead Hosp, Wentworthville, Australia
[2] Sir Charles Gairdner Hosp, Nedlands, WA, Australia
[3] Univ WA, Nedlands, WA, Australia
[4] Univ Newcastle, Newcastle, NSW, Australia
[5] Cabrini Hlth Private Hosp, Malvern, Australia
[6] Kosan Biosci, Hayward, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8558
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Effect of heat-shock protein-90 (HSP90) inhibition on human hepatocytes and on liver regeneration in experimental models
    Hackl, Christina
    Mori, Akira
    Moser, Christian
    Lang, Sven A.
    Dayoub, Rania
    Weiss, Thomas S.
    Schlitt, Hans J.
    Geissler, Edward K.
    Hellerbrand, Claus
    Stoeltzing, Oliver
    SURGERY, 2010, 147 (05) : 704 - 712
  • [22] Heat Shock Protein 90 (Hsp90) in Fungal Growth and Pathogenesis
    Lamoth F.
    Juvvadi P.R.
    Steinbach W.J.
    Current Fungal Infection Reports, 2014, 8 (4) : 296 - 301
  • [23] Role of Heat Shock Protein 90 (Hsp90) in Insulin Secretion
    Tamarina, Natalia A.
    Philipson, Louis H.
    DIABETES, 2013, 62 : A575 - A576
  • [24] Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors
    Wang, Yao
    Koay, Yen Chin
    McAlpine, Shelli R.
    CHEMISTRY-A EUROPEAN JOURNAL, 2017, 23 (09) : 2010 - 2013
  • [25] The role of secreted heat shock protein-90 (Hsp90) in wound healing - how could it shape future therapeutics?
    Guo, Jiacong
    Chang, Cheng
    Li, Wei
    EXPERT REVIEW OF PROTEOMICS, 2017, 14 (08) : 665 - 675
  • [26] Heat Shock Protein 90 (Hsp90) Expression and Breast Cancer
    Zagouri, Flora
    Bournakis, Evangelos
    Koutsoukos, Konstantinos
    Papadimitriou, Christos A.
    PHARMACEUTICALS, 2012, 5 (09): : 1008 - 1020
  • [27] Phase I study of vemurafenib and heat shock protein 90 (HSP90) inhibitor XL888 in metastatic BRAF V600 mutant melanoma.
    Eroglu, Zeynep
    Gibney, Geoffrey Thomas
    Weber, Jeffrey S.
    Kudchadkar, Ragini Reiney
    Khushalani, Nikhil I.
    Markowitz, Joseph
    Tetteh, Leticia F.
    Ramadan, Howida
    Zhao, Xiuhua
    Chen, Ann
    Sharma, Ritin
    Messina, Jane
    Koomen, John M.
    Sondak, Vernon K.
    Smalley, Keiran
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] RET Is a Heat Shock Protein 90 (HSP90) Client Protein and Is Knocked Down upon HSP90 Pharmacological Block
    Alfano, Luigi
    Guida, Teresa
    Provitera, Livia
    Vecchio, Giancarlo
    Billaud, Marc
    Santoro, Massimo
    Carlomagno, Francesca
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (07): : 3552 - 3557
  • [29] Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) plus trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Modi, S.
    Sugarman, S.
    Stopeck, A.
    Linden, H.
    Ma, W.
    Kersey, K.
    Johnson, R. G.
    Rosen, N.
    Hannah, A. L.
    Hudis, C. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] Potent Triazolothione Inhibitor of Heat-Shock Protein-90
    Feldman, Richard I.
    Mintzer, Bob
    Zhu, Daguang
    Wu, James M.
    Biroc, Sandra L.
    Yuan, Shendong
    Emayan, Kumar
    Chang, Zheng
    Chen, Deborah
    Arnaiz, Damian O.
    Bryant, Judi
    Ge, Xue Snow
    Whitlow, Marc
    Adler, Marc
    Polokoff, Mark A.
    Li, Wei-Wei
    Ferrer, Mike
    Sato, Takashi
    Gu, Jian-Ming
    Shen, Jun
    Tseng, Jih-Lie
    Dinter, Harald
    Buckman, Brad
    CHEMICAL BIOLOGY & DRUG DESIGN, 2009, 74 (01) : 43 - 50
12345